Finally, it’s too late for your mother, but older people who have not had the newer two-dose shingles vaccine (Shingrix) ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

New study reveals potential cognitive benefits of Shingrix vaccine. The shingles shot may offer protection against dementia, especially in women.

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Adults should discuss with their doctors about whether this vaccine is necessary. It is recommended that adults 50 and older ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

The drugmaker’s U.S. expansion comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% ...

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit ...

The company faces challenges in developing a single-dose shingles vaccine candidate that meets non-inferiority margins compared to Shingrix. Q: With the updated 2030 market view, does the previous ...

Choose wisely, experts say, when you pick your Medicare Part D prescription drug plan for 2025. What's in the formulary ...

Dynavax Technologies (NASDAQ: DVAX) Q3 2024 Earnings Call Nov 07, 2024, 4:30 p.m. ET ...